Stifel Maintains a Hold Rating on Revvity (RVTY)

Revvity, Inc. (NYSE:RVTY) is one of the Best Mid Cap Value Stocks to Buy in 2026. On March 13, Stifel maintained a Hold rating on Revvity, Inc. (NYSE:RVTY) with a price target of $110.

​The rating follows the firm’s meeting with the management of Revvity, where management expressed cautious optimism regarding certain parts of the business and the end market. Management noted that their 2026 guidance assumes a steady‑state environment, with pharma and biotech growth around low‑single digits, similar to 2025. Within that, management highlights positive indicators, including higher activity in high-content screening, improved biotech funding, and continued pharma and biotech M&A.

​Management noted that the cautious outlook stems from weak academic demand along with some short-term organic growth headwinds, such as weaker demand from China and slower on-premises software renewals. The firm sees 2026 as an important year for the company, as it believes that any macro-economic recovery or acceleration in biotech funding can drive upside.

​Revvity, Inc. (NYSE:RVTY) offers advanced health science solutions across multi-omics, imaging, biomarkers, and informatics segments.

While we acknowledge the risk and potential of RVTY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RVTY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Flying Penny Stocks to Buy and 10 Cheap Stocks to Buy for High Returns in 2026.

Disclosure: None. Follow Insider Monkey on Google News.